Chronic Toxoplasma infection is associated with distinct alterations in the synaptic protein composition.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Schott, Björn H
van Ham, Marco
Gundelfinger, Eckart D
Smalla, Karl Heinz
Dunay, Ildiko Rita
MetadataShow full item record
AbstractChronic infection with the neurotropic parasite Toxoplasma gondii has been implicated in the risk for several neuropsychiatric disorders. The mechanisms, by which the parasite may alter neural function and behavior of the host, are not yet understood completely. Here, a novel proteomic approach using mass spectrometry was employed to investigate the alterations in synaptic protein composition in a murine model of chronic toxoplasmosis. In a candidate-based strategy, immunoblot analysis and immunohistochemistry were applied to investigate the expression levels of key synaptic proteins in glutamatergic signaling. A comparison of the synaptosomal protein composition revealed distinct changes upon infection, with multiple proteins such as EAAT2, Shank3, AMPA receptor, and NMDA receptor subunits being downregulated, whereas inflammation-related proteins showed an upregulation. Treatment with the antiparasitic agent sulfadiazine strongly reduced tachyzoite levels and diminished neuroinflammatory mediators. However, in both conditions, a significant number of latent cysts persisted in the brain. Conversely, infection-related alterations of key synaptic protein levels could be partly reversed by the treatment. These results provide evidence for profound changes especially in synaptic protein composition in T. gondii-infected mice with a downregulation of pivotal components of glutamatergic neurotransmission. Our results suggest that the detected synaptic alterations are a consequence of the distinct neuroinflammatory milieu caused by the neurotropic parasite.
AffiliationHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States
- Toxoplasma gondii antigens recognized by IgG antibodies differ between mice with and without active proliferation of tachyzoites in the brain during the chronic stage of infection.
- Authors: Hester J, Mullins J, Sa Q, Payne L, Mercier C, Cesbron-Delauw MF, Suzuki Y
- Issue date: 2012 Oct
- The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
- Authors: Jost C, Reiter-Owona I, Liesenfeld O
- Issue date: 2007 Nov
- Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
- Authors: Khan AA, Lambert LH Jr, Remington JS, Araujo FG
- Issue date: 1999 Apr
- Kinetics of systemic cytokine and brain chemokine gene expression in murine toxoplasma infection.
- Authors: Aviles H, Stiles J, O'Donnell P, Orshal J, Leid J, Sonnenfeld G, Monroy F
- Issue date: 2008 Dec
- Chronic murine toxoplasmosis is defined by subtle changes in neuronal connectivity.
- Authors: Parlog A, Harsan LA, Zagrebelsky M, Weller M, von Elverfeldt D, Mawrin C, Korte M, Dunay IR
- Issue date: 2014 Apr